| Identification | Back Directory | [Name]
1H-Cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-1-acetamide, N-[(1S)-1-[3-[4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, sodium salt (1:1), (3bS,4aR)- | [CAS]
2283356-12-5 | [Synonyms]
Lenacapavir sodium
1H-Cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-1-acetamide, N-[(1S)-1-[3-[4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, sodium salt (1:1), (3bS,4aR)- | [Molecular Formula]
C39H33ClF10N7NaO5S2 | [MOL File]
2283356-12-5.mol | [Molecular Weight]
992.28 |
| Hazard Information | Back Directory | [Uses]
Lenacapavir (GS-6207) sodium is a HIV-1 capsid inhibitor. Lenacapavir sodium shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells. Lenacapavir sodium displays a mean EC50 of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs)[1]. | [References]
[1] Singh K, et al. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front Microbiol. 2019 Jun 20;10:1227. DOI:10.3389/fmicb.2019.01227 |
|
| Company Name: |
Elucigen bio
|
| Tel: |
13501719342; 13501719342 |
| Website: |
|
|